StemCells (STEM) PT Cut to $3 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
StemCells, Inc. Announces Strategic Realignment
December 23, 2015 8:05 AM ESTNEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ: STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Companys resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).
Evidence of efficacy from the Companys ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function previously considered unrecoverable. StemCells recently reported a pattern of improvements in both... More
